Moderna, Inc. (NASDAQ:MRNA) Director Noubar Afeyan Sells 15,000 Shares

Moderna, Inc. (NASDAQ:MRNA - Get Free Report) Director Noubar Afeyan sold 15,000 shares of Moderna stock in a transaction dated Wednesday, April 24th. The shares were sold at an average price of $108.32, for a total value of $1,624,800.00. Following the transaction, the director now directly owns 2,041,931 shares in the company, valued at approximately $221,181,965.92. The transaction was disclosed in a legal filing with the SEC, which is available through this link.

Noubar Afeyan also recently made the following trade(s):

• On Wednesday, April 17th, Noubar Afeyan sold 15,000 shares of Moderna stock. The shares were sold at an average price of $103.38, for a total value of $1,550,700.00.
• On Wednesday, April 10th, Noubar Afeyan sold 15,000 shares of Moderna stock. The shares were sold at an average price of $107.12, for a total value of $1,606,800.00.
• On Wednesday, April 3rd, Noubar Afeyan sold 15,000 shares of Moderna stock. The shares were sold at an average price of $101.68, for a total value of $1,525,200.00.
• On Wednesday, March 27th, Noubar Afeyan sold 15,000 shares of Moderna stock. The shares were sold at an average price of $109.06, for a total value of $1,635,900.00.
• On Wednesday, March 20th, Noubar Afeyan sold 15,000 shares of Moderna stock. The stock was sold at an average price of $102.39, for a total value of $1,535,850.00.
• On Wednesday, March 13th, Noubar Afeyan sold 15,000 shares of Moderna stock. The shares were sold at an average price of $108.54, for a total value of $1,628,100.00.

Moderna Stock Performance

NASDAQ:MRNA traded up $1.79 during mid-day trading on Friday, hitting $107.97. 2,245,667 shares of the stock were exchanged, compared to its average volume of 4,077,747. The stock has a market capitalization of $41.34 billion, a price-to-earnings ratio of -8.70 and a beta of 1.62. The firm's 50-day simple moving average is $102.54 and its 200 day simple moving average is $93.77. The company has a debt-to-equity ratio of 0.04, a quick ratio of 3.36 and a current ratio of 3.42. Moderna, Inc. has a fifty-two week low of $62.55 and a fifty-two week high of $142.79.

Moderna (NASDAQ:MRNA - Get Free Report) last issued its quarterly earnings results on Thursday, February 22nd. The company reported $0.55 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.78) by $1.33. Moderna had a negative return on equity of 10.23% and a negative net margin of 68.84%. The company had revenue of $2.80 billion for the quarter, compared to analyst estimates of $2.53 billion. During the same quarter last year, the company posted $3.61 EPS. The company's revenue for the quarter was down 44.9% compared to the same quarter last year. As a group, equities analysts anticipate that Moderna, Inc. will post -7.51 EPS for the current fiscal year.

Institutional Investors Weigh In On Moderna

A number of hedge funds and other institutional investors have recently bought and sold shares of MRNA. First Pacific Financial acquired a new position in shares of Moderna in the 3rd quarter valued at about $27,000. Ogorek Anthony Joseph NY ADV acquired a new position in Moderna during the 4th quarter worth approximately $27,000. Arlington Trust Co LLC raised its stake in Moderna by 4,833.3% during the 4th quarter. Arlington Trust Co LLC now owns 296 shares of the company's stock worth $29,000 after buying an additional 290 shares during the period. Westside Investment Management Inc. acquired a new position in Moderna during the 1st quarter worth approximately $32,000. Finally, Rise Advisors LLC raised its stake in Moderna by 953.3% during the 1st quarter. Rise Advisors LLC now owns 316 shares of the company's stock worth $34,000 after buying an additional 286 shares during the period. Institutional investors own 75.33% of the company's stock.

Analysts Set New Price Targets

MRNA has been the topic of several research reports. William Blair reaffirmed a "market perform" rating on shares of Moderna in a research note on Monday, April 1st. HSBC reissued a "reduce" rating and issued a $86.00 target price (up previously from $75.00) on shares of Moderna in a research note on Monday, February 26th. Jefferies Financial Group restated a "buy" rating and issued a $125.00 price target on shares of Moderna in a report on Tuesday, April 9th. Oppenheimer upgraded Moderna from a "market perform" rating to an "outperform" rating and set a $142.00 price target for the company in a report on Tuesday, January 2nd. Finally, Royal Bank of Canada reiterated an "outperform" rating and set a $125.00 price objective on shares of Moderna in a report on Thursday, March 28th. Two analysts have rated the stock with a sell rating, eight have assigned a hold rating and six have given a buy rating to the company. According to MarketBeat.com, the company has a consensus rating of "Hold" and a consensus price target of $126.49.

Moderna Company Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.